Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Phase 2 Interventional Results available

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

NCT06164743
View directory record Official record
Conditions
Inflammation
Interventions
VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Inglewood, California • Petaluma, California • Rancho Cordova, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 2:55 AM EDT
Completed No phase listed Observational

Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema

NCT02088229
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Phase 2 Interventional

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT00051194
View directory record Official record
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
Combination IOP Lowering Therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 24, 2026, 2:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of the Ocular Microbiome in Health and Disease

NCT05414994
View directory record Official record
Conditions
Microbial Colonization, Eye Diseases, Ophthalmopathy
Interventions
Eye swab
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 2:55 AM EDT
Recruiting Phase 3 Interventional

Pilocarpine Use After Kahook Goniotomy

NCT03933631
View directory record Official record
Conditions
Glaucoma
Interventions
Pilocarpine, Prednisolone, Ofloxacin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years to 100 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 24, 2026, 2:55 AM EDT
Active, not recruiting Phase 2 Interventional

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

NCT00716066
View directory record Official record
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Role of Spectral Filtering in a Spectrally Adjustable Ocular Photosensitivity Analyzer

NCT04811079
View directory record Official record
Conditions
Photosensitivity
Interventions
419 nm Spectacle Filter, 437 nm Spectacle Filter, 456 nm Spectacle Filter, 476 nm Spectacle Filter, 373 nm Spectacle Filter
Other
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 24, 2026, 2:55 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Ocular Hypertension And Yoga Study

NCT01446588
View directory record Official record
Conditions
Ocular Hypertension, Sleep Disturbance, Stress, Anxiety, Depression
Interventions
Yoga Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 24, 2026, 2:55 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Senseye's OBCI Diagnostic Tool for PTSD

NCT05372523
View directory record Official record
Conditions
PTSD
Interventions
CAPS-5 Assessment, Senseye OBCI
Diagnostic Test
Lead sponsor
Senseye, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Phase 4 Interventional

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US

NCT00847483
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
40
States / cities
Bellflower, California • Inglewood, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 24, 2026, 2:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Human Plasticity in the Human System

NCT00001661
View directory record Official record
Conditions
Blindness, Cerebrovascular Accident, Spinal Cord Injury
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Phase 4 Interventional

Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK

NCT00889941
View directory record Official record
Conditions
Myopia
Interventions
LASIK
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 24, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Isolating and Mitigating Sequentially Dependent Perceptual Errors in Clinical Visual Search

NCT04332783
View directory record Official record
Conditions
Vision
Interventions
psychophysics of sequential biases (no drug or patient work)
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
10,120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2032
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional

Effectiveness of Rituximab in Pediatric OMS Patients.

NCT00244361
View directory record Official record
Conditions
Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia
Interventions
rituximab
Drug
Lead sponsor
National Pediatric Neuroinflammation Organization, Inc.
Other
Eligibility
6 Months to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Oct 24, 2026, 2:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rates and Risk Factors of Contact Between the OTX-TIC Intracameral Ocular Implant and Corneal Endothelium

NCT05835141
View directory record Official record
Conditions
Corneal Endothelium
Interventions
OCT Imaging
Other
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 24, 2026, 2:55 AM EDT
Recruiting Phase 4 Interventional

Evaluation of Lacrifill

NCT07796178
View directory record Official record
Conditions
Dry Eye, Ocular Surface Disease, Cataract Surgery, Eyes Dry Feeling of
Interventions
Lacrifill, Saline
Drug
Lead sponsor
Eye Research Associates, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburg, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

NCT00934089
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 24, 2026, 2:55 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

NCT06891443
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
Interventions
sepofarsen, Placebo IVT
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
6 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

inVENT-visIOn Study

NCT01444391
View directory record Official record
Conditions
Otitis Media
Interventions
Tympanostomy tube placement (Acclarent iontophoresis device)
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
6 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 24, 2026, 2:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992
View directory record Official record
Conditions
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Interventions
Tepotinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
39
States / cities
Duarte, California • Encinitas, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 24, 2026, 2:55 AM EDT
Not listed Phase 2 Interventional

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

NCT00546936
View directory record Official record
Conditions
Presumed Ocular Histoplasmosis (POHS)
Interventions
ranibizumab, verteporfin
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2009 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Not applicable Interventional Results available

Toric Intraocular Lens Following Cataract Surgery

NCT01140477
View directory record Official record
Conditions
Cataract, Astigmatism
Interventions
Toric Accommodating Lens, Accommodating Lens
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 24, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Results available

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

NCT02065375
View directory record Official record
Conditions
Inflammation and Pain Following Ocular Surgery
Interventions
Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Fort Myers, Florida • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 24, 2026, 2:55 AM EDT
Recruiting Not applicable Interventional

4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800

NCT07024719
View directory record Official record
Conditions
Corneal Diseases, Retinal Diseases, Ocular Diseases
Interventions
4D MIOCT integrated into a Zeiss Artevo 800
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 2:55 AM EDT